Compare Novo Nordisk A/S (NVO) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Schwab US Dividend Equity ETF — how do they compare? Novo Nordisk A/S trades at $46.45 (market cap $207.85B), while Schwab US Dividend Equity ETF trades at $34.27. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Schwab US Dividend Equity ETF pays none, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SCHD | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $34.27 |
52-Week Low | $35.29 | $26.44 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
SCHD trades at $34.26, showing modest daily gains of 0.2% with strong bullish technical signals from moving averages. The ETF maintains its position as a core dividend equity holding, though key valuation metrics remain unavailable in current data. Recent institutional activity shows Barry Investment Advisors increased their position by 29.9% during Q2 2026, indicating continued institutional confidence in the fund's strategy.
SCHD faces competition from alternative income ETFs while benefiting from the current market rotation toward value strategies. The fund's 2% yield and dividend-focused approach appeal to retirement investors, though tax efficiency considerations remain crucial for optimal positioning. Market sentiment suggests SCHD serves as a defensive holding in volatile environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
